Key takeaway: The earnings call for Narayana Hrudayalaya Limited on August 3, 2026, discussed the company's performance for the quarter ended June 30, 2026. Management highlighted a 40% EBITDA growth despite no new bed additions in recent years, attributing this to increased high-end procedures and technology use. They noted a rise in patient footfalls, contributing to revenue growth alongside average revenue per occupied bed (ARPOB). However, management acknowledged challenges in the insurance segment, citing a spike in losses due to a few large claims and the small size of the insurance book. They emphasized ongoing initiatives to improve claims management and portfolio sustainability. The management also addressed the UK business, indicating early integration challenges but expressing optimism about future growth and margin improvement. Overall, the call reflected a focus on operational efficiency and strategic growth across domestic and international markets.

Key takeaway: The investor presentation from Narayana Hrudayalaya Ltd. for the quarter ended June 30, 2026, reported a consolidated operating revenue of ₹26,836 million, reflecting a 78.0% year-over-year increase and a 3.5% quarter-over-quarter increase. The presentation highlighted significant operational achievements, including 2,137 cardiac surgeries performed and the introduction of advanced medical technologies at various facilities. The consolidated EBITDA was reported at ₹5,052 million with a margin of 18.8%, while the consolidated PAT stood at ₹2,073 million, representing a margin of 7.7%. The company also outlined its digital transformation initiatives and ESG vision, aiming for improved healthcare access and sustainability. The shareholding pattern indicated that the promoter group held 63.3% of the shares, with significant institutional investments from various asset management firms.

Key takeaway: The investor presentation for Narayana Hrudayalaya Ltd. for the quarter ended June 30, 2026, reported consolidated operating revenues of ₹26,836 million, reflecting a 78.0% year-over-year increase and a 3.5% quarter-over-quarter increase. The presentation highlighted significant operational achievements, including 2,137 cardiac surgeries performed and the introduction of advanced medical technologies at various facilities. The consolidated EBITDA was reported at ₹5,052 million with a margin of 18.8%, while the consolidated PAT stood at ₹2,073 million, representing a margin of 7.7%. The company also outlined its digital transformation initiatives and ESG vision, aiming for improved healthcare access and sustainability. The shareholding pattern as of June 30, 2026, indicated that the promoter group held 63.3% of the shares. The presentation concluded with a summary of ongoing and future capital expenditure projects.

Key takeaway: The investor presentation for Narayana Hrudayalaya Ltd. for the quarter and financial year ended March 31, 2026, reported significant growth in both operational and financial metrics. The company achieved consolidated operating revenues of ₹25,938 million in Q4 FY26, reflecting a 75.8% year-over-year increase, and ₹78,960 million for FY26, a 44.0% increase. EBITDA for Q4 FY26 was ₹5,392 million with a margin of 20.8%, while FY26 EBITDA reached ₹17,169 million at a margin of 21.7%. The presentation highlighted advancements in clinical services, including over 750 robotic cardiac surgeries performed in FY26. The company also reported a net debt to equity ratio of 0.49 as of March 31, 2026. Additionally, Narayana Health outlined its digital transformation initiatives and ESG vision aimed at improving healthcare access and sustainability.

Key takeaway: The earnings call for Narayana Hrudayalaya Limited, held on February 17, 2026, discussed the company's performance for the quarter ended December 31, 2025. Management reported significant profit growth in the India business, attributing this to transformation programs and improved payor mix optimization. They noted a margin expansion of 150-200 basis points year-over-year. However, management indicated that while they aim to maintain these margins, they could not provide specific guidance on future performance. The call also addressed the company's insurance segment, which is still in a building phase, and the challenges faced in the northern cluster due to competition and receivable issues. Management emphasized their focus on consolidating operations in core markets and expanding services, particularly in oncology and robotic surgeries. The UK operations were discussed, highlighting the need for operational efficiencies and the potential for growth despite current losses. Overall, the management expressed optimism about future growth prospects across various segments.

Key takeaway: The investor presentation for Narayana Hrudayalaya Ltd. for the quarter ended December 31, 2025, reported consolidated operating revenues of ₹21,512 million, reflecting a 61.2% year-over-year increase and a 30.9% quarter-over-quarter increase. The presentation highlighted significant operational achievements, including a 35% increase in robotic cardiac surgeries and the successful completion of the first heart transplant at Narayana Multi-specialty Hospital, Ahmedabad. The consolidated EBITDA was reported at ₹3,904 million with a margin of 18.2%, while the consolidated PAT stood at ₹1,281 million, representing a margin of 6.0%. The document also detailed ongoing expansion projects and digital transformation initiatives aimed at enhancing patient care and operational efficiency. Additionally, the presentation outlined the company's ESG vision, emphasizing health accessibility and sustainability goals. The shareholding pattern as of December 31, 2025, indicated a promoter group ownership of 63.3%.